Get the Stockscreener App
1.17
4.46%
0.05
After Hours:
1.18
0.01
+0.85%
Beyondspring Inc stock is traded at $1.17, with a volume of 9,765.
It is up +4.46% in the last 24 hours and down -30.77% over the past month.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
See More
Previous Close:
$1.12
Open:
$1.11
24h Volume:
9,765
Relative Volume:
0.41
Market Cap:
$48.11M
Revenue:
$1.88M
Net Income/Loss:
$-8.48M
P/E Ratio:
-6.2201
EPS:
-0.1881
Net Cash Flow:
$-19.13M
1W Performance:
-5.65%
1M Performance:
-30.77%
6M Performance:
-27.33%
1Y Performance:
-39.06%
1-Day Range:
$1.11
$1.19
1-Week Range:
$0.994
$1.31
52-Week Range:
$0.994
$2.44
Beyondspring Inc Stock (BYSI) Company Profile
Name
Beyondspring Inc
Sector
Industry
Phone
646-528-4184
Address
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.17 | 46.05M | 1.88M | -8.48M | -19.13M | -0.1881 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-02-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-01-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-09-21 | Initiated | Robert W. Baird | Outperform |
| Aug-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-05-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-21 | Initiated | BofA Securities | Buy |
| Dec-29-20 | Initiated | Evercore ISI | Outperform |
| Feb-07-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | Nomura | Buy |
| Dec-03-19 | Initiated | William Blair | Outperform |
| Jul-10-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-19 | Downgrade | Maxim Group | Buy → Hold |
| Oct-25-18 | Reiterated | Maxim Group | Buy |
View All
Beyondspring Inc Stock (BYSI) Latest News
Beyondspring Inc (BYSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BYSI|Beyondspring Inc|Price:1.150|Chg%:+0.030 - TradingKey
Beyondspring Inc (BYSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beyondspring Inc (BYSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
BeyondSpring, Inc. Revenue Breakdown – NASDAQ:BYSI - TradingView
Beyondspring Inc (BYSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Na (nl) Li Net Worth (2026) - GuruFocus
Min Qiu Net Worth (2026) - GuruFocus
BeyondSpring (BYSI) Q1 2026 Earnings: EPS Loss of -$0.05 Amid No Revenue and Stock DeclineGuidance vs Actual - DonanımHaber
Form 4 BeyondSpring Inc For: 6 July By Investing.com - Investing.com Nigeria
BeyondSpring (BYSI) CEO Qiu Min reports direct holding of 2,498 Ordinary Shares - Stock Titan
BeyondSpring (BYSI) director receives 100,000 stock options grant - Stock Titan
BeyondSpring (BYSI) CFO Li Na submits initial Form 3 ownership filing - Stock Titan
BYSI Q1 2026 Earnings: Narrowing Net Loss Reinforces Strategic FocusConsensus Miss Rate - dars.gov.et
BeyondSpring Inc. (BYSI) Edges Higher with Modest Gains, Testing Key Resistance LevelsTRIN Signal - dars.gov.et
BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Narrowing Per‑Share Loss Amid Ongoing Pipeline FocusBalance Sheet Strength - dars.gov.et
BeyondSpring (BYSI) finalizes CEO Min Qiu salary, bonus and option grant - Stock Titan
BeyondSpring Inc.(NasdaqCM: BYSI) dropped from Russell 3000E Growth Benchmark - marketscreener.com
BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
BYSI Q1 2026 Earnings: Narrowed Loss as Pipeline AdvancesEarnings Preview - dars.gov.et
BYSI Q1 2026 Earnings: Narrowing Losses Amid Pipeline Progress, Stock Gains 5.6%Pre-Earnings Drift - dars.gov.et
Beyondspring Inc (BYSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Price to sales forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Enterprise value to revenue forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Beyondspring Inc (BYSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BeyondSpring Inc. Actuals & Estimates (NASDAQ:BYSI) - TradingView
BYSI Q1 2026 Earnings: Loss Per Share Narrows as Clinical Pipeline AdvancesEPS Growth Report - dars.gov.et
BeyondSpring Inc. (BYSI) Slips 2.48%: Stock Tests Key Support at $1.49TPO Profile - dars.gov.et
BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Narrowing Losses Amid Strategic Clinical ProgressRevenue Growth Report - dars.gov.et
BYSI Q1 2026 Earnings: Narrowing Loss and Clinical Progress Drive Modest Stock GainQuarterly Financial Update - dars.gov.et
Beyondspring Inc (BYSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beyondspring Inc (BYSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Beyondspring Inc (BYSI) Institutional Confidence - TradingKey
BYSI Q1 2026 Earnings: Net Loss Narrows Amid Ongoing Clinical DevelopmentProfitability Analysis - newsline.com
BYSI Q1 2026 Earnings: Pipeline Progress Amidst Pre-Revenue PhaseEarnings Quality Score - dars.gov.et
BeyondSpring Announces Major Leadership Transition and New CEO - The Globe and Mail
BYSI Q1 2026 Earnings: Loss per Share of $0.05, Stock Declines Amid Quiet QuarterEarnings Season Outlook - dars.gov.et
BeyondSpring names new CEO as founder transitions to chairman role - StreetInsider
BeyondSpring Elevates Min Qiu to CEO, Names Na Li CFO in Leadership Transition - citybiz
BeyondSpring names new CEO, CFO as founder shifts to chairman role By Investing.com - Investing.com South Africa
BeyondSpring Inc. Announces Appointment of Na Li as Chief Financial Officer, Effective July 1, 2026 - marketscreener.com
BeyondSpring names new CEO, CFO as founder shifts to chairman role - Investing.com Nigeria
BeyondSpring (NASDAQ: BYSI) overhauls leadership to drive DUBLIN-4 lung cancer program - Stock Titan
BeyondSpring Inc. Announces Leadership Transition to Enhance Focus on DUBLIN-4 Program and Plinabulin Development - Quiver Quantitative
BeyondSpring: Lan Huang Remains Chairman >BYSI - Moomoo
BeyondSpring Announces Leadership Transition to Deliver - GlobeNewswire
BeyondSpring (BYSI) Shares Promising Phase 2 Findings for Lung C - GuruFocus
BeyondSpring reports phase 2 lung cancer trial results at ASCO - Investing.com
BeyondSpring reports phase 2 lung cancer trial results at ASCO By Investing.com - Investing.com Canada
Lung cancer trial tests drug trio after immunotherapy, 58% alive at 2 years - Stock Titan
Beyondspring Inc Stock (BYSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):